US resumes shipping antibody treatments that may be ineffective against omicron

The federal government has resumed shipping all three COVID-19 monoclonal antibody treatments to systems across the U.S. despite evidence two of the three may be ineffective in treating omicron, The Washington Post reported Jan. 9. 

Read the full post at Becker's Hospital Review - Healthcare News
Vote This Post DownVote This Post Up (No Ratings Yet)
Explore the Archive